MX2018008531A - Compuestos del metabolito del antagonista del receptor de angiotensina ii y del inhibidor de nep, y metodos de preparacion de los mismos. - Google Patents

Compuestos del metabolito del antagonista del receptor de angiotensina ii y del inhibidor de nep, y metodos de preparacion de los mismos.

Info

Publication number
MX2018008531A
MX2018008531A MX2018008531A MX2018008531A MX2018008531A MX 2018008531 A MX2018008531 A MX 2018008531A MX 2018008531 A MX2018008531 A MX 2018008531A MX 2018008531 A MX2018008531 A MX 2018008531A MX 2018008531 A MX2018008531 A MX 2018008531A
Authority
MX
Mexico
Prior art keywords
angiotensin
preparation
composite
receptor antagonist
nep inhibitor
Prior art date
Application number
MX2018008531A
Other languages
English (en)
Inventor
Yan Jie
Wang Yang
ZHI Jianqiong
Li Song
Zheng Yanxin
Xu Wenjie
Original Assignee
Shenzhen Salubris Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharm Co Ltd filed Critical Shenzhen Salubris Pharm Co Ltd
Publication of MX2018008531A publication Critical patent/MX2018008531A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En esta invención se proporcionan una serie de complejos supermoleculares (compuestos) con doble acción que están compuestos por el compuesto con efecto bloqueante del receptor de angiotensina II (AT1), inhibidor de neprilisina (NEPi) y sus cationes farmacéuticamente aceptables.
MX2018008531A 2016-01-20 2017-01-19 Compuestos del metabolito del antagonista del receptor de angiotensina ii y del inhibidor de nep, y metodos de preparacion de los mismos. MX2018008531A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201610038846 2016-01-20
CN201610193099 2016-03-30
CN201610430248 2016-06-16
PCT/CN2017/071625 WO2017125031A1 (zh) 2016-01-20 2017-01-19 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法

Publications (1)

Publication Number Publication Date
MX2018008531A true MX2018008531A (es) 2019-05-15

Family

ID=59361369

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008531A MX2018008531A (es) 2016-01-20 2017-01-19 Compuestos del metabolito del antagonista del receptor de angiotensina ii y del inhibidor de nep, y metodos de preparacion de los mismos.

Country Status (11)

Country Link
US (1) US11026925B2 (es)
EP (1) EP3406610A4 (es)
KR (1) KR102150383B1 (es)
CN (2) CN114315801B (es)
AU (1) AU2017209250B2 (es)
CA (1) CA3016258A1 (es)
MX (1) MX2018008531A (es)
RU (1) RU2723642C1 (es)
TW (1) TWI657826B (es)
WO (1) WO2017125031A1 (es)
ZA (1) ZA201805376B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
CN113286789B (zh) * 2019-05-30 2022-03-11 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途
US20220226285A1 (en) * 2019-05-30 2022-07-21 Shenzhen Salubris Pharmaceuticals Co., Ltd. Treatment Method Using A Complex of Angiotensin II Receptor Antagonist Metabolite and NEP Inhibitor
MX2022003408A (es) * 2019-09-20 2022-07-12 Shenzhen Salubris Pharm Co Ltd Usos del complejo de metabolito antagonista del receptor de angiotensina ii e inhibidor de nep en el tratamiento de la insuficiencia cardiaca.
WO2021093697A1 (zh) * 2019-11-11 2021-05-20 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂与nep抑制剂的复合物及其制备方法
CN114945564B (zh) * 2020-01-19 2023-06-30 深圳信立泰药业股份有限公司 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法
CN116036079A (zh) * 2020-06-18 2023-05-02 深圳信立泰药业股份有限公司 一种复合物的药物组合物及其制备方法
TW202228677A (zh) * 2020-08-17 2022-08-01 大陸商深圳信立泰藥業股份有限公司 血管收縮素ｉｉ受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用
TW202228671A (zh) * 2020-11-25 2022-08-01 大陸商深圳信立泰藥業股份有限公司 Ａｒｂ代謝產物與ｎｅｐ抑制劑的複合物在製備用於預防和／或治療腎病的藥物中的用途
TW202327582A (zh) * 2021-08-26 2023-07-16 大陸商深圳信立泰藥業股份有限公司 ＡＲＮｉ與鈣離子拮抗劑的藥物組合物及其用途
CN118176190A (zh) * 2022-08-04 2024-06-11 深圳信立泰药业股份有限公司 ARNi化合物新晶型及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
CN105503760A (zh) 2014-10-10 2016-04-20 上海翰森生物医药科技有限公司 结晶型ARB-NEPi双阳离子复合物及其制备方法和应用
CN110801452B (zh) * 2015-03-12 2023-01-13 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯水解产物或其水解产物盐的药物组合物及其用途
CN106146472A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的阿利沙坦复合物
CN106138041A (zh) * 2015-04-15 2016-11-23 苏州朗科生物技术有限公司 一种双重作用的氯沙坦复合物
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
CN105669581B (zh) 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物

Also Published As

Publication number Publication date
AU2017209250A1 (en) 2018-09-06
CN114315801B (zh) 2023-06-20
KR20180128393A (ko) 2018-12-03
EP3406610A1 (en) 2018-11-28
EP3406610A4 (en) 2019-09-04
US20200061025A1 (en) 2020-02-27
TWI657826B (zh) 2019-05-01
KR102150383B1 (ko) 2020-09-02
CN108473474B (zh) 2022-02-11
CA3016258A1 (en) 2017-07-27
WO2017125031A1 (zh) 2017-07-27
RU2723642C1 (ru) 2020-06-17
TW201726177A (zh) 2017-08-01
AU2017209250B2 (en) 2021-07-29
CN108473474A (zh) 2018-08-31
US11026925B2 (en) 2021-06-08
CN114315801A (zh) 2022-04-12
ZA201805376B (en) 2019-06-26

Similar Documents

Publication Publication Date Title
MX2018008531A (es) Compuestos del metabolito del antagonista del receptor de angiotensina ii y del inhibidor de nep, y metodos de preparacion de los mismos.
NZ763551A (en) Compounds useful for inhibiting cdk7
MX2020005484A (es) Formas solidas de un inhibidor de calicreina en plasma y sales del mismo.
TN2014000155A1 (en) Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014100719A3 (en) Teatrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
MY202135A (en) Uses of neuroactive compounds
MX369576B (es) Imidazoles 2-piridilo sustituidos como inhibidores de alk5 y/o alk4.
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
MX350875B (es) Formas de dosificacion farmaceutica de liberacion controlada.
PH12015501940A1 (en) Dihydropyridazine-3,5-dione derivative
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
EP3785511A4 (en) SPREADING ASSISTANT SYSTEM FOR WORK MACHINE
WO2014066799A3 (en) Modulators of resistant androgen receptor
WO2016196646A8 (en) Cannabinoid receptor mediating compounds
PH12016501841A1 (en) Immunosuppressant formulation
PH12016502246B1 (en) Carboxamide derivatives
MX2016014946A (es) Derivados de carboxamida.
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
MX2019011639A (es) Formulacion farmaceutica.
MX2019002149A (es) Metodo para el tratamiento de prurito y/o comezon.
PH12017501314A1 (en) Composite capsules comprising raloxifene, and vitamin d or its derivatives
MX2020013352A (es) Tratamiento para migrañas.
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
EP4011393A4 (en) PHARMACEUTICAL AGENT FOR TRANSMUCOSAL ADMINISTRATION